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Administration of a single large dose of 7,12-dimethylbenz(a)anthracene
(9,10-dimethyl-1,2-benzanthracene, DMBA) to Sprague-Dawley rats leads to the
development of mammary tumours within 6-8 weeks (Huggins, Grand and
Brillantes, 1961). It also results in the destruction of the inner zones of the
adrenal cortex within 2-3 days (Huggins and Morii, 1961) but this occurs only
after DMBA has been metabolized by the liver (Wheatley, Kernohan and Currie,
1966). Impairment of liver function by CC14 or partial hepatectomy, whilst
preventing the adrenocorticolytic effect of DMBA injection, fails to influence
mammary tumour induction significantly (Kernohan, Inglis and Wheatley, 1967).
It is considered improbable, therefore, that mammary tumours are induced by a
metabolite ofDMBA produced in the liver.
DMBA is metabolized in the rat liver mainly by hydroxylation of its methyl
side groups, unlike many other polycyclic hydrocarbons which undergo ring
hydroxylation (Boyland and Sims, 1965). Hydroxymethyl derivatives-7-
hydroxymethyl-12-methylbenz(a)anthracene (7-OHM-MBA), 12-hydroxymethyl-
7-methylbenz(a)anthracene (12-OHM-MBA) and 7-hydroxymethyl-12-hydroxy-
methylbenz(a)anthracene (7-OHM-12-OHM-BA)-have been identified as products
of DMBA after incubation with rat liver homogenates. Their ability to induce
mammary tumours was investigated by Boyland, Sims and Huggins (1965) who
found that the 7-hydroxymethyl derivative was carcinogenic but slower in
producing tumours than DMBA whereas the 12-hydroxymethyl derivative was
inactive. The results of our investigations with these derivatives form the basis
of this report.
MATERIALS AND METHODS
Sprague-Dawley female rats from an accredited stock were obtained from
Oxford Laboratory Animal Colonies, Bicester, Oxon, England. They were
treated with polycyclic compounds at 50 days of age when weighing about 150 g.
They were fed modified Thompson rat cube containing 14 % skimmed milk (North-
Eastern Agricultural Co-operative Society Ltd., Aberdeen, Scotland) and allowed
water ad libitum. They were kept in groups of 5 rats per cage at a room tempera-
ture of 21-22° C. (70-72° F.) with natural daylight hours.
7,12-dimethylbenz(a)anthracene (DMBA), 7-hydroxymethyl-12-methylbenz(a)
anthracene (7-OHM-MBA), 12-hydroxymethyl-7-methylbenz(a)anthracene (12-
OHM-MBA) and 7-hydroxymethyl-12-hydroxymethylbenz(a)anthracene (7-OHM-
12-OHM-BA) were dissolved in olive oil at concentrations of 10 and 15 mg./ml.
In making up the compounds at these concentrations, the more hydrophilic
derivatives remained to some extent in suspension rather than solution. TheMAMMARY TUMOURS INDUCED BY DMBA AND DERIVATIVES
solutions were given to rats by stomach tube in doses of 1 0 ml. at the lower
concentration (10 mg. dose) or 2-0 ml. at the higher concentration (30 mg. dose)
after a 4-hour period of fasting.
Commencing 4 weeks after injection, rats were palpated each week for tumours.
Tumours were measured and charted as described by Stevens, Stevens and
Currie (1965). The animals were killed 6 months after injection and examined
for tumours. Sections (5 ,t) stained with haematoxylin and eosin were prepared
from every tumour or suspected tumour after fixation in 4% neutral buffered
formaldehyde and paraffin wax embedding.
RESULTS
Fig. 1 shows the percentage ofrats with palpable tumours against time.
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FIG. 1.-Percentage ofrats bearing palpable mammary tumours against time after treatment of
50-day Sprague-Dawley female rats with DMBA and its hydroxymethyl derivatives. The
inflexions towards the end of the curves for both 10 mg. and 30 mg. DMBA treatments
introduce those rats with no palpable tumours which were found to have tumours at necropsy
on week 26, so that the final figures attain the true percentage of tumour-bearing rats.
1. 10 mg. DMBA
2. 30 mg. DMBA
3. 10 mg. 7-OHM-MBA
4. 30 mg. 7-OHM-MBA
5. 10 mg. 12-OHM-MBA
6. 30 mg. 12-OHM-MBA
7. 10 mg. 7-OHM-12-OHM-BA
8. 30 mg. 7-OHM-12-OHM-BA
Table I gives an analysis of the induced tumours.
DMBA at 10 mg. and 30 mg. had comparable tumour inducing properties in our
rats with respect to both time at which tumours became palpable (referred to as
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the " latent period of induction ", more precisely the latent period of detection)
and the percentage ofrats producing tumours. In terms ofyield, the 10 mg. dose
induced more tumours than the 30 mg. dose.
Mammary tumours were induced in about one-tenth ofthe rats receiving either
10 or 30 mg. doses of 7-OHM-MBA. They became detectable no later than the
average detection time for DMBA-induced tumours. None of the 3 induced
tumours grewprogressively.
Only 1 rat treated with 12-OHM-MBA produced a tumour (a rapidly growing
adenocarcinoma) out of a total of 40 rats, the rat in question having received a
30 mg. dose.
The dihydroxymethyl derivative, 7-OHM-12-OHM-BA, failed to produce
mammary tumours.
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FIG. 2.-Survival of rats following intragastric treatment with 10 mg. 7-OHM-MBA ( )
or 30 mg. 7-OHM-MBA (
Histologically the vast majority of tumours were adenocarcinomas, but there
was 1 tumour in the 10 mg. DMBA group and 4 tumours in the 30 mg. DMBA
group which were fibroadenomas.
No fibromas or ear duct tumours were induced by DMBA or its derivatives in
this experiment. One rat given 30 mg. 7-OHM-MBA died 24 weeks after inject-
ion with hepatosplenomegaly, having a reticulosis which was tentatively identi-
fied as a lymphogenous leukaemia. A similar reticulosis was found in a rat
given 30 mg. DMBA.
During the first week of the experiment, some of the rats treated with DMBA
or 7-OHM-MBA died with severe adrenal necrosis. In most of the groups occa-
sional deaths were recorded through the 6 month observation period usually due to
pneumonia, the rats being excluded from the final assessment oftumour incidence
(Table I). In the groups given 10 mg. and 30 mg. 7-OHM-MBA, about a third of
the rats died within the first week after treatment. Whereas no deaths were
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found after the first week in rats given 10 mg. 7-OHM-MBA, deaths occurred
throughout the subsequent 6 months in rats given 30 mg. 7-OHM-MBA (Fig. 2).
At the end of the experiment only 7 out of 30 rats in the latter group were alive,
of which 2 were very sick and had fibroadenomatous lesions of the kidneys. One
rat dying at 10 weeks also had fibroadenomatous lesions ofthe kidneys. Thirteen
ofthe original 30 rats dies between 1 week and 6 months after injection; common
features at necropsy were pleural effusion and adhesions, which were not correlated
with the presence of pneumonia.
DISCUSSION
The hydroxymethyl derivatives of DMBA do not have potent mammary
tumour inducing properties. The monohydroxymethyl derivatives induced an
occasional tumour but the dihydroxymethyl derivative proved entirely inactive.
Our results with 7-OHM-MBA, involving larger groups ofrats and 2 different dose
levels, are in contrast to those of Boyland, Sims and Huggins (1965) who found
this derivative possessed considerable carcinogenic activity at the 10 mg. dose
level but produced tumours more slowly than DMBA.
Our results lead to the conclusion that hydroxylation of the methyl side
groups of DMBA is not essential for mammary tumour induction, unlike the
metabolic conversion to the 7-hydroxymethyl derivative which appears necessary
for adrenocorticolysis to occur (Wheatley, Kernohan and Currie, 1966). This
confirms our earlier observation (Kernohan, Inglis and Wheatley, 1967) that
DMBA probably does not have to undergo metabolism in the liver before acting
as a mammary gland carcinogen.
It is of interest that the monohydroxymethyl derivatives of DMBA are not
entirely devoid of the ability to induce mammary tumours. It is improbable
that tumours were induced by DMBA contaminating the derivatives since the
amounts present were undetectable in a test system previously calculated to be
sensitive to a 0,1% contamination level of DMBA (Sims, P., personal communi-
cation). The critical amount ofDMBA for tumour induction in our rats is of the
order of several mg.; in the doses of derivatives administered, the amount of
DMBA contamination was, therefore, far below this critical level. One possibility
is that some of the monohydroxymethyl derivative is converted to DMBA.
Alternatively the monohydroxymethyl derivatives may be metabolized to the
same " proximate carcinogen " in the mammary gland as DMBA but with
considerably less efficiency. However, the possibility remains that the mono-
hydroxymethyl compounds are in themselves very weak carcinogens whose
actions are independent of their structural affinity to the parent molecule.
We have found considerable variability in the relative tumour inducing
properties of 10 and 30 mg. doses of DMBA in our rats. Sometimes, as in the
experiment reported here, the smaller dose induces more tumours than the larger
dose. It appears that there is an optimal dose level above which tumour induction
is not increased. At the higher dose level the carcinogen may be effecting the
destruction of cells rather than their transformation to the neoplastic state. There
is a greater incidence of adrenal damage in rats treated with the 30 mg. DMBA
and therefore adrenal insufficiency during the period shortly after treatment with
the carcinogen could also be affecting the process of tumour induction in this
group. This latter possibility is being examined.
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The present investigation also emphasizes the need for thorough inspection of
every animal at necropsy. Mammary pads showing any abnormality should be
removed and examined histologically. With the 10 and 30 mg. dose levels of
DMBA, a total of 40 out of 97 tumours were found at necropsy. Many of the
tumours were of the histological type B described by Stevens, Stevens and Currie
(1965). They were not detectable with any certainty by palpation through the
skin of the rat because of the smallness of their size and/or their rather diffuse
nature. Although in this experiment the number of tumours found at necropsy
was higher than usual, their presence tends to make the commonly used graphical
representation of percentage of tumour-bearing rats against time (as in Fig. 1)
meaningless unless it is emphasized that it represents only those rats with readily
palpable tumours.
SUMMARY
Female Sprague-Dawley rats were treated intragastrically with 10 mg. or
30 mg. 7,12-dimethylbenz(a)anthracene, 7-hydroxymethyl-12-methylbenz(a)anth-
racene, 12-hydroxymethyl-7-methylbenz(a)anthracene or 7-hydroxymethyl-12-
hydroxymethylbenz(a)anthracene in olive oil, and mammary tumour induction
was studied over the subsequent 6 months.
In contrast to the potent mammary tumour inducing properties of 7,12-
dimethylbenz(a)anthracene, the monohydroxymethyl derivatives induced tumours
in only an occasional rat, and the dihydroxymethyl derivative proved inactive.
In this experiment, the yield of mammary tumours induced by the 10 mg.
dose of 7,12-dimethylbenz(a)anthracene was slightly higher than that induced by
the 30 mg. dose.
Many tumours, impalpable during life, were discovered at necropsy. The
presence of such tumours makes it difficult to assess the true incidence of tumour-
bearing rats in a living population at any time after the administration of the
carcinogen.
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